Yarrow Bioscience (NASDAQ:YARW) Sees Significant Growth in Short Interest

Yarrow Bioscience (NASDAQ:YARW) was the target of a large increase in short interest in August. As of August 14th, there was short interest totaling 19,427 shares, an increase of 54.4% from the July 30th total of 12,582 shares. Based on an average daily volume of 17,382 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.8% of the company’s stock are sold short.

Yarrow Bioscience Price Performance

NASDAQ:YARW traded down $0.09 during mid-day trading on Tuesday, hitting $32.88. 3,577 shares of the company’s stock traded hands, compared to its average volume of 13,762. Yarrow Bioscience has a twelve month low of $14.02 and a twelve month high of $46.95. The firm has a market capitalization of $87.78 million, a P/E ratio of -2.25 and a beta of 1.96.

Analyst Upgrades and Downgrades

YARW has been the topic of a number of recent research reports. TD Cowen initiated coverage on shares of Yarrow Bioscience in a research note on Tuesday, July 28th. They set a “buy” rating on the stock. BTIG Research initiated coverage on shares of Yarrow Bioscience in a research note on Monday, August 3rd. They issued a “buy” rating and a $58.00 price objective for the company. Finally, Wall Street Zen upgraded Yarrow Bioscience to a “hold” rating in a report on Saturday, August 22nd. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $58.00.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.